Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F9 Genotype and Pharmacokinetics in Hemophilia B (Nonacog alfa)
2017-003902-42Phase 4Terminated
- Sponsor
- Consorzio Futuro in Ricerca
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Consorzio Futuro in Ricerca. Primary endpoint: Expression levels of recombinant proteins bearing patients' F9 mutations. Started Dec 2017; status: terminated.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2017-003902-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003902-42.